Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring AMR bacterial pneumonia

Abstract

Here we describe the case of a COVID-19 patient who developed recurring ventilator-associated pneumonia caused by Pseudomonas aeruginosa that acquired increasing levels of antimicrobial resistance (AMR) in response to treatment. Metagenomic analysis revealed the AMR genotype, while immunological analysis revealed massive and escalating levels of T-cell activation. These were both SARS-CoV-2 and P. aeruginosa specific, and bystander activated, which may have contributed to this patient's persistent symptoms and radiological changes.

Data availability

Human-filtered sequencing data for this study have been deposited in the European Nucleotide Archive (ENA) at EMBL-EBI under accession PRJEB40239.

The following data sets were generated

Article and author information

Author details

  1. Michaela Gregorova

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1605-0558
  2. Daniel Morse

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Tarcisio Brignoli

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Joseph Steventon

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Fergus Hamilton

    Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Mahableshwar Albur

    Pathology, North Bristol NHS Trust, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9792-7280
  7. David Arnold

    Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3158-7740
  8. Matthew Thomas

    Intensive Care Unit, North Bristol NHS Trust, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. Alice Halliday

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Holly Baum

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Christopher Rice

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Matthew B Avison

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  13. Andrew D Davidson

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1136-4008
  14. Marianna Santopaolo

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  15. Elizabeth Oliver

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  16. Anu Goenka

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  17. Adam Finn

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  18. Linda Wooldridge

    Bristol Veterinary School in the Faculty of Health Sciences, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  19. Borko Amulic

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  20. Rosemary J Boyton

    Lung Immunology Group, Section of Infectious Disease and Immunity, Department of Medicine, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, Centre for Respiratory Infection Imperial College, Imperial College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  21. Daniel M Altmann

    Human Disease Immunogenetics Group, Section of Infectious Disease and Immunity, Department of Medicine, Imperial College London W12 ONN, Imperial College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  22. David K Butler

    Lung Immunology Group, Section of Infectious Disease and Immunity, Department of Medicine, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, Centre for Respiratory Infection Imperial Coll, Imperial College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  23. Claire McMurray

    Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  24. Joanna Stockton

    Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  25. Sam Nicholls

    Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  26. Charles Cooper

    Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  27. Nicholas Loman

    Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  28. Michael J Cox

    Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  29. Laura Rivino

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    For correspondence
    laura.rivino@bristol.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
  30. Ruth C Massey

    School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
    For correspondence
    ruth.massey@bristol.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8154-4039

Funding

Southmead Hospital Charity

  • Fergus Hamilton

Wellcome Trust (212258/Z/18/Z)

  • Ruth C Massey

Elizabeth Blackwell Institute

  • Laura Rivino

UKRI (MR/S019553/1)

  • Rosemary J Boyton

UKRI (MR/R02622X/1)

  • Daniel M Altmann

Cystic Fibrosis Trust (CF Trust SRC 015)

  • David K Butler

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The patient was enrolled onto the DISCOVER study (Diagnostic and Severity markers of COVID-19 to Enable Rapid triage study), a single centre prospective study recruiting consecutive patients admitted with COVID-19, from 30.03.2020 until present (Ethics approval via South Yorkshire REC: 20/YH/0121, CRN approval no: 45469). Blood/serum samples from pre-pandemic healthy controls and asymptomatic healthy controls were obtained under the Bristol Biobank (NHS Research Ethics Committee approval ref 14/WA/1253).

Copyright

© 2020, Gregorova et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,117
    views
  • 348
    downloads
  • 25
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Michaela Gregorova
  2. Daniel Morse
  3. Tarcisio Brignoli
  4. Joseph Steventon
  5. Fergus Hamilton
  6. Mahableshwar Albur
  7. David Arnold
  8. Matthew Thomas
  9. Alice Halliday
  10. Holly Baum
  11. Christopher Rice
  12. Matthew B Avison
  13. Andrew D Davidson
  14. Marianna Santopaolo
  15. Elizabeth Oliver
  16. Anu Goenka
  17. Adam Finn
  18. Linda Wooldridge
  19. Borko Amulic
  20. Rosemary J Boyton
  21. Daniel M Altmann
  22. David K Butler
  23. Claire McMurray
  24. Joanna Stockton
  25. Sam Nicholls
  26. Charles Cooper
  27. Nicholas Loman
  28. Michael J Cox
  29. Laura Rivino
  30. Ruth C Massey
(2020)
Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring AMR bacterial pneumonia
eLife 9:e63430.
https://doi.org/10.7554/eLife.63430

Share this article

https://doi.org/10.7554/eLife.63430

Further reading

    1. Microbiology and Infectious Disease
    McKenna Harpring, Junghoon Lee ... John V Cox
    Research Article

    Chlamydia trachomatis serovar L2 (Ct), an obligate intracellular bacterium that does not encode FtsZ, divides by a polarized budding process. In the absence of FtsZ, we show that FtsK, a chromosomal translocase, is critical for divisome assembly in Ct. Chlamydial FtsK forms discrete foci at the septum and at the base of the progenitor mother cell, and our data indicate that FtsK foci at the base of the mother cell mark the location of nascent divisome complexes that form at the site where a daughter cell will emerge in the next round of division. The divisome in Ct has a hybrid composition, containing elements of the divisome and elongasome from other bacteria, and FtsK is recruited to nascent divisomes prior to the other chlamydial divisome proteins assayed, including the PBP2 and PBP3 transpeptidases, and MreB and MreC. Knocking down FtsK prevents divisome assembly in Ct and inhibits cell division and septal peptidoglycan synthesis. We further show that MreB does not function like FtsZ and serve as a scaffold for the assembly of the Ct divisome. Rather, MreB is one of the last proteins recruited to the chlamydial divisome, and it is necessary for the formation of septal peptidoglycan rings. Our studies illustrate the critical role of chlamydial FtsK in coordinating divisome assembly and peptidoglycan synthesis in this obligate intracellular bacterial pathogen.

    1. Microbiology and Infectious Disease
    Tao Tang, Weiming Zhong ... Zhipeng Gao
    Research Article

    Saprolegnia parasitica is one of the most virulent oomycete species in freshwater aquatic environments, causing severe saprolegniasis and leading to significant economic losses in the aquaculture industry. Thus far, the prevention and control of saprolegniasis face a shortage of medications. Linalool, a natural antibiotic alternative found in various essential oils, exhibits promising antimicrobial activity against a wide range of pathogens. In this study, the specific role of linalool in protecting S. parasitica infection at both in vitro and in vivo levels was investigated. Linalool showed multifaceted anti-oomycetes potential by both of antimicrobial efficacy and immunomodulatory efficacy. For in vitro test, linalool exhibited strong anti-oomycetes activity and mode of action included: (1) Linalool disrupted the cell membrane of the mycelium, causing the intracellular components leak out; (2) Linalool prohibited ribosome function, thereby inhibiting protein synthesis and ultimately affecting mycelium growth. Surprisingly, meanwhile we found the potential immune protective mechanism of linalool in the in vivo test: (1) Linalool enhanced the complement and coagulation system which in turn activated host immune defense and lysate S. parasitica cells; (2) Linalool promoted wound healing, tissue repair, and phagocytosis to cope with S. parasitica infection; (3) Linalool positively modulated the immune response by increasing the abundance of beneficial Actinobacteriota; (4) Linalool stimulated the production of inflammatory cytokines and chemokines to lyse S. parasitica cells. In all, our findings showed that linalool possessed multifaceted anti-oomycetes potential which would be a promising natural antibiotic alternative to cope with S. parasitica infection in the aquaculture industry.